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In vitro evaluation of PEGylated mesoporous MgFe2O4
magnetic nanoassemblies (MMNs) for chemo-thermal
therapy†
Sunil Kumar,a Amita Daverey,‡b Niroj Kumar Sahub and Dhirendra Bahadur*b
A size tunable synthesis of mesoporous MgFe2O4 magnetic nanoassemblies (MMNs) through a PEG-diacid
mediated polyol method is reported. The PEG-diacid coated MMNs exhibit a significant specific surface
area of 92 m2 g1 and saturation magnetization of 57 emu g1. These MMNs exhibit a very good
colloidal stability in PBS (pH 7.4) with nonappreciable cytotoxicity in mouse fibroblast (L929) and cervical
cancer (HeLa) cells. We demonstrate the potential of MMNs as an integrated nanosystem for drug
delivery and magnetic hyperthermia (MHT) through in vitro studies. 80% loading efficiency of
doxorubicin (DOX) has been achieved due to the highly negative surface charge and mesoporous
nature of MMNs. It is observed that 65–70% of HeLa cells undergo apoptosis through DNA
fragmentation after 24 h of incubation with DOX loaded MMNs. MHT alone induces the death of 40–
45% of cells, whereas the synergistic effect of a combination of DOX and MHT leads to the death of
about 90% of cells. Our results show that MHT significantly increases the therapeutic efficacy of DOX to
induce more apoptosis in cancer cells. Hence, a combination of MHT with chemotherapy makes MMNs a
powerful multimodal system for synergistic chemo-thermal cancer therapy.
1 Introduction
Chemotherapy is the rst line therapy for the treatment of
cancer. But several disadvantages associated with this therapy
such as nonselective distribution of drugs, multidrug resis-
tance, undesirable side effects on normal tissue and other
physical inconveniences to the patients resulted in researchers
developing alternative approaches for the improved treatment
of cancer. Nano drug-delivery systems have been shown to
reduce some side effects of chemotherapy associated with non-
selective distribution and the toxic effects of drugs.1,2 Besides
delivery of the drug to the tumour sites, advanced nano-
materials have been shown to open doors to dual-therapies.
Moving in this direction, nanomaterials having the function-
alities of hyperthermia and chemotherapy in a single system
are more in demand for cancer treatment. Several studies have
shown that the therapeutic efficacy of any anticancer drug such
as doxorubicin (DOX) can be enhanced by combination with
hyperthermia.3,4 Different nanostructures such as gold nano
shells,5 carbon nanotubes,6 graphene,7 and magnetic nano-
particles3,8 have been used extensively for the chemo-thermal
ablation of tumours. Among these, oxide magnetic nano-
particles (MNPs) have emerged as a better option due to their
good biocompatibility, degradability under mild acidic condi-
tions, magnetic manipulation, magnetic resonance imaging
(MRI) properties and capability to generate controlled non-
invasive heat under an alternating current (AC) magnetic eld
(AMF).8–10 MNPs have been used for several drug delivery
applications, but one of the limitations is their ability to carry a
large amount of anticancer drug at tumour sites. To enhance
the drug carrying capacity of MNPs, various nanohybrid drug
delivery carriers such as peptide mimic shell cross-linked
magnetic nanocarriers (PMNCs),11 magnetic liposomes,8 algi-
nate embedded magnetic nanoheaters3 etc. have been devel-
oped. However, these nanohybrids also have problems such as
large size, complex design and non-reproducibility. Recently,
mesoporous12 and hollow nanoparticles13 have emerged as
promising candidates for dual therapy due to their capability
to hold a large amount of anticancer drug at the tumour site
and minimize systemic drug toxicity. These features of meso-
porous nanoparticles are attributed to their large surface area
and pore volume.12 Previous studies have reported the
synthesis of water dispersible mesoporous magnetic nano-
assemblies (MMNs) using polyacrylic acid,14 trisodium
citrate,15 and poly-g-glutamic acid12 as stabilizing agents.
However, these methods have their limitations with respect to
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biocompatibility or the large size of the magnetic nano-
assemblies (>200 nm). Large nanoassemblies cannot be effi-
ciently injected into the body intravenously as a drug carrier.
In addition, due to large size of the particles, they are easily
sequestered by the spleen and removed by the phagocyte
system of the body resulting in the reduction of blood circu-
lation time.16,17 Therefore, new methods and suitable stabi-
lizing agents are needed to synthesize ideal magnetic
nanoassemblies uniquely capable of drug delivery, imaging
and magnetic hyperthermia.
In the present work, we have prepared a novel, highly water
dispersible, biocompatible and size tunable (<100 nm) meso-
porous MgFe2O4 magnetic nanoassemblies (MMNs) by a polyol
method using PEG-diacid as a stabilizing agent. The advan-
tages of the synthesized MMNs over other nanoassemblies and
nanoparticles are (i) their size range lies between the renal
clearance threshold (8 nm) and the gap in leaky cancer blood
vessels (100 nm), which is good to exploit passive tumour
targeting through enhanced permeation and retention effect
(EPR),16 (ii) PEG modication on the surface of the MMNs
helps in resisting the adsorption of unwanted plasma protein
and increases the colloidal stability for prolonged blood
circulation, and (iii) MMNs are more biocompatible due to the
presence of Mg2+ ions which are required for ATP hydrolysis
for energy generation, genomic stability and catalytic activity of
almost all enzymatic systems involved in DNA processing.18,19
The potential applications of these MMNs were evaluated for
DOX delivery and magnetic hyperthermia (Scheme 1). DOX was
loaded into mesoporous MMNs through electrostatic interac-
tion, henceforth referred to in the text as DOX–MMNs. We
compared the combined effect of chemotherapy and MHT with
individual treatments in human cervix adenocarcinoma HeLa
cells. Our results show the novelty and potential of DOX–
MMNs for synergistic combination therapy leading to
apoptosis through DNA fragmentation and cell membrane
distortion. The enhancement of the DOX efficacy and the
synergistic effect with MHT to induce more cell death make
MMNs a powerful nanosystem for chemo-thermal cancer
therapy.
2 Experimental section
2.1 Reagents and materials
All the chemicals were of analytical grade and used as received.
Iron(III) chloride hexahydrate (FeCl3$6H2O, 99%), magnesiu-
m(II) chloride hexahydrate (MgCl2$6H2O, 99%), doxorubicin–
HCl salt (DOX, $98%), poly(ethylene glycol)bis(carboxy methyl)
ether (HOOC–PEG–COOHMn 600), 3-(4,5-dimethyl-thiazol-2yl)-
2,5-diphenyl tetrazolium bromide (MTT, >98%), 4,6-diamidino-
2-phenylindole (DAPI, >98%), propidium iodide (PI, >94%),
ethidium bromide (EtBr, >95%), and rhodamine-6G (99%) and
phalloidin-tetramethyl rhodamine-B-isothiocyanate conjugates
were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium (inner salts, MTS) and phenazine
methoxysulfonate were procured from Promega (PMS), Madi-
son, USA. Sodium borohydride (NaBH4, Merck, 98%), sodium
acetate (CH3COONa, Aldrich, 99%) and ethylene glycol (EG,
Merck, 99.8%) were used in the reaction. Dulbecco's modied
eagle medium (DMEM), antibiotic and antimycotic solution
were obtained from Hi-Media Ltd (Mumbai, India) and L929
and HeLa cell lines were procured from the National Center of
Cell Science (NCCS, Pune, India). Milli-Q water (18.2 MU cm)
was used throughout the experiments.
2.2 Synthesis procedure for MMNs
In a typical synthesis procedure, FeCl3$6H2O (3.7 mM, 1 g) and
MgCl2$6H2O (1.9 mM, 0.38 g) in a molar ratio of 2 : 1, PEG-
diacid (3.5 g, 600 g per mole), and sodium acetate (NaAc,
CH3COONa, 3 g) were dissolved in 15 mL of EG in a 100 mL
three neck round bottom ask. The mixture was heated to
180 C in an inert (N2 gas) environment for 30 min. A solution of
sodium borohydride (0.05 g in 10 mL of EG) was prepared and
injected into the reaction vessel at 180 C. It was then reuxed
for 8 h at 200 C. The solution was cooled down to room
temperature in an inert protected environment and the black
precipitates were obtained by repeatedly washing with ethanol
and Milli-Q water using a magnetic separation method.
2.3 Characterization techniques
The identication and purity of the phase were determined by
X-ray diffraction (XRD) using a Philips powder diffractometer
(PW3040/60) with Cu Ka radiation (l ¼ 1.5405 A˚) and a Ni lter.
The average crystallite size was calculated using the Scherrer
relationship. Fourier transform infrared spectra of the dried
powder samples were recorded using an FTIR instrument
(Magna550, Nicolet Instruments Corporation, USA) using the
KBr pellet technique. Thermal analysis was carried out in a
thermo gravimetric–differential thermal analysis instrument
(SDT Q100, USA). The samples under examination were heated
from room temperature to 650 C at a rate of 10 C min1 in a
nitrogen atmosphere. The specic surface area, pore volume
and pore size distribution of the MMNs were measured using a
Micromeritics instrument (ASAP 2020). Prior to measurement,
the sample was degassed at 120 C for 6 h. The microstructure
and surface morphology of the samples were analysed using a
Scheme 1 Schematic representation of carboxyl enriched PEGylated MMNs
synthesis and evaluation of their efficiency for chemo-thermal treatment against
cancer cells.
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transmission electron microscope (TEM, JEOL JEM-2100F) and
eld emission scanning electron microscope (FEGSEM, JEOL
JEM-7600F). The composition of the sample was determined by
the energy dispersive X-ray spectroscopy (EDX) technique.
Weight chemical analysis was performed using an inductively
coupled plasma-atomic emission spectrometer (ICP-AES,
ARCOS, and Germany). Magnetic properties of the samples were
measured in a Quantum design magnetic properties measure-
ment system (PPMS).
2.4 In vitro DOX loading and release
DOX–MMN conjugates were prepared using electrostatic inter-
actions between positively charged doxorubicin (DOX) and the
negatively charged MMNs. The maximum loading amount of
DOX into the pores of the MMNs was determined by the serial
addition of MMNs (10, 50, 100, 150, 200, and 300 mg mL1) to a
xed concentration of DOX solution (16 mg mL1 in 600 mL of
PBS, pH 7.4) and the uorescence was monitored at excitation
with 480 nm, and the emission was recorded in the range 500–
750 nm using a Hitachi F 2500 spectrouorometer. To examine
the loading efficiency, a standard curve was plotted with known
concentrations of DOX dissolved in PBS at pH 7.4. The amount
of DOX loaded (DLoaded) into the nanoparticles was calculated as
follows:
Dloaded ¼ Dtotal  Dsupernatant (1)
where, Dtotal is the amount of drug added for loading and
Dsupernatant is the amount of drug calculated from the superna-
tant aer the settling of the MMNs by an external magnet.
Furthermore, the loading efficiency of DOX into the MMNs was
calculated using following equation:
% efficiency ¼ Dloaded
Dtotal
 100 (2)
The in vitro drug release prole of the DOX–MMNs was
determined by loading DOX–MMNs (5 mg) samples into a
dialysis bag (Himedia, dialysis membrane-150, LA401), which
was submerged in 5 mL of phosphate-buffered saline (PBS,
pH ¼ 7.4) and acetate buffer of pH 5.2 at 37 C. The dialysate
was taken out aer a specic time interval to estimate the
amount of drug released while the same amount of fresh buffer
of the respective pH was added and kept in the shaker for
further experimentation. The DOX concentration in the sample
was measured by uorescence intensity at lexcitation ¼ 480 nm
and lemission in the range 500–750 nm using a Hitachi F 2500
spectrouorometer.
2.5 Cell culture
The cell culture experiments were carried out with L929 and
HeLa cell lines. L929 cells were grown in DMEM medium
(Himedia Laboratories Pvt Ltd, Mumbai, India) and HeLa cells
were grown in DMEM medium supplemented with 10% fetal
bovine serum and an antibiotic–antimycotic mix (Himedia
Laboratories Pvt Ltd, Mumbai, India) at 37 C in a humidied
and 5% CO2 atmosphere (InCu-safe).
2.6 Rhodamine-6G–MMNs uptake by HeLa cells
Uptake of MMNs by HeLa cells was studied using confocal
microscopy. MMNs were labelled with a positively charged
uorescent dye, rhodamine-6G by incubating MMNs (2 mg
mL1 in PBS, pH 7.4) with rhodamine-6G (1 mg mL1) with
constant shaking for 12 h at room temperature. HeLa cells were
plated on coverslips at a density of 1  105 cells per well in a 12-
well plate. Aer 24 h, the cells were incubated with 0.1 mgmL1
rhodamine-labeled MMNs for 4 and 24 h. The cells were washed
3 times with PBS (pH 7.4), xed with 4% paraformaldehyde,
mounted on a glass slide and then examined with an IX81
FV500 laser scanning confocal microscope (Olympus, Tokyo,
Japan). The images were digitally magnied 6 times using
FluoView soware (Olympus, Tokyo, Japan).
2.7 In vitro biocompatibility of MMNs
The biocompatibility of MMNs was evaluated for L929 cells by
using an MTS proliferation assay kit (Promega). For cytotoxicity
assays, L929 cells were cultured (2  104 cells per well) in 96-
well plates for 24 h. Aer incubation, the old media was
replaced by fresh media containing bare MMNs in the
concentration range 0.05 to 0.6 mg mL1 and again incubated
for another 24 and 48 h. Aer incubation, the old media was
removed and 20 mL of MTS/PMS solution in 100 mL of DMEM
media was added to each well. The plate was then incubated for
3 h and the absorbance at 490 nm was measured using a micro
plate reader (Perkin Elmer 1420). The formazan dye generated
by the live cells was proportional to the number of live cells.
Cells without nanoparticles were considered as a control. The
results were quantied by manually subtracting the blank value
from each value then normalizing against the control.
2.8 In vitro antitumour efficacy of DOX–MMNs
HeLa cells were used to examine the in vitro antitumour efficacy
of DOX–MMNs. Briey, 2  104 cells per well were seeded in 96-
well plate. Aer incubation for 24 h, different concentrations of
DOX–MMNs (10 to 120 mg mL1) were added in ve replicates.
HeLa cells cultured in the absence of DOX–MMNs acted as
controls. Aer being cultured for 24 and 48 h, the viability of the
HeLa cells was determined using the MTS assay as described
above. The IC50 values of the DOX–MMNs were expressed as the
free DOX concentrations (1 to 7 mg mL1). The results were
quantied by subtracting the blank value from each value and
then normalizing against the control.
2.9 Subcellular localization study of DOX–MMNs
1  105 HeLa cells were seeded on a coverslip. Aer 24 h, the
cells were treated with 0.1 mg mL1 DOX–MMNs for 4 h fol-
lowed by incubation for 30 min with 1 mM of Lysotracker Red
DND-99 (Invitrogen). The cells were then xed in 4% para-
formaldehyde, and the nuclei were stained with DAPI (Calbio-
chem) for 10 min. Three-channel, optical images (DAPI, DOX,
and Lysotracker Red) were collected using the sequential
scanning mode (405, 480, and 543 nm excitation; 450, 560, and
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595 nm emission) of an IX81 FV500 laser scanning confocal
microscope (Olympus, Tokyo, Japan).
2.10 Cell morphological assessment of apoptosis
To detect morphological evidence of apoptosis, the cell nuclei
were visualized following DNA staining with the uorescent
nuclear dye, ethidium bromide (EtBr). Briey, cells were seeded
at a concentration of 1  105 cells per well on the coverslip in
12-well tissue culture plates and treated with DOX–MMNs
(0.1 mg of MMNs per mL, 20 mg equivalent DOX per mL) for 4,
24 and 48 h. At the end of the incubation, the cells were washed
thoroughly with PBS, xed with 70% ethanol and incubated
with EtBr (12 mM) for 10 min. The cells were again washed with
PBS, mounted on a glass slide and then examined with an IX81
FV500 laser scanning confocal microscope.
2.11 In vitro magnetic hyperthermia experiments
The heating ability of the MMN suspension in PBS was obtained
from time dependent calorimetric measurements using an
induction heating unit (Comdel CLF-5000, Ameritherm) oper-
ating at frequency of 425 kHz. In brief, 0.5 mg of MMNs per mL
(approximate metal ion concentration) in PBS was subjected to
AC magnetic elds (AMFs) of 7 kA m1 and 10 kA m1, at a
frequency of 425 kHz, to evaluate the specic absorption rate
(SAR). The SAR was calculated using the following equation:





where C is the specic heat of the solvent (Cwater¼ 4.18 J g1 C),
DT/Dt is the initial slope of the time-dependent temperature
curve and mFe is the mass fraction of Fe in PBS.
For the in vitro magnetic hyperthermia treatment (MHT)
experiments, HeLa cells were grown up to 90% conuency in a
25 cm2 culture ask. The culture medium was replaced with
2 mL of PEGylated MMNs dispersed in DMEM media at a
concentration of 0.5 mg of MMNs per mL. Aer 24 h, the DMEM
medium was removed and the cell layer was washed three times
with PBS, detached from the substratum and pelleted by
centrifugation. The cellular pellet was then transferred to a
2 mL Teon sample vial, yielding concentrations of 2  106
HeLa cells per 1 mL of PBS. The cells were nally exposed to a
magnetic hyperthermia setup, by applying an alternating
magnetic eld at a frequency of 425 kHz and at a magnetic eld
amplitude of 7 kA m1 for 5 min to raise the temperature to 43–
45 C. The same procedure was also performed for DOX–MMNs
to evaluate their combined effect for cancer cell death. For a
comparative study, HeLa cells were treated using MHT alone
(without MMNs and DOX) and, DOX–MMNs (0.5 mg mL1,
20 mg equivalent DOX per mL) with and without MHT. Cells
without any treatment were used as a control. Aer the thermal
treatment, the HeLa cells were centrifuged and settled with a
magnet. The cell pellet was washed three times with PBS. Then,
100 mL of a 2  106 cells per mL solution was seeded in 96 well
plates in 16 replicates, followed by incubation for 24 h in a 5%
CO2 incubator. The morphological features of the treated cells
were observed by actin staining with phalloidin-
tetramethylrhodamine-B-isothiocyanate and the nucleus by 4,6-
diamidino-2-phenylindole (DAPI) according to the protocol of
Sigma-Aldrich. 3-(4,5-Dimethyl-thiazol-2yl)-2,5-diphenyl tetra-
zolium bromide (MTT) as well as a live/dead assay were used for
cell viability studies. For the MTT assay, the cell culture super-
natant was replaced with 100 mL of fresh medium containing
10 mL of 5 mgmL1 MTT. The plates were then incubated for 4 h
at 37 C. The purple formazan crystals were dissolved in 50%
DMF in a water solution containing 5% SDS (sodium dodecyl
sulfate). Thereaer, the absorbance was measured at a wave-
length of 550 nm in a plate reader.
The cell viability percentage was calculated using the
following equation:
Cell viability ¼
Absorbance of the treated well with MMNs
Absorbance of control
 100 (4)
For the live/dead assay, the treated cells were stained with
calcein AM (2 mM) and ethidium homodimer-1 (4 mM) for
30 min. The cells were observed using an IX81 FV500 laser
scanning confocal microscope (Olympus, Tokyo, Japan).
3 Results and discussion
3.1 Structural characterization of MMNs
The microstructure and surface morphology of the as-synthe-
sized MMNs were observed by SEM (Fig. 1a and b) and TEM (see
ESI, Fig. S1a–c†). Themicrostructures show that the particles are
spherical and porous. The submicron sized (>250 nm) nano-
assemblies were formed in the absence of an external reducing
agent but a reduction in the size of nanoassemblies (<100 nm)
was obtained in the presence of an extra reducing agent, sodium
borohydride (NaBH4). The addition of a strong reducing agent
during the reaction initiated a super saturation state that led to
the formation of a large number of nuclei and subsequent
assembling resulted in the evolution of smaller MMNs.20 The
XRD pattern of the MMNs shows a typical face centered cubic
inverse spinel structure (Fig. S2a†). The crystallite size estimated
from the peak broadening corresponding to the (311) plane
using the Debye–Scherrer equation was found to be 11.5 nm.
A lattice parameter of 8.32 A˚ and a unit cell volume of 577 A˚3
were obtained. A comparison of the crystallite size (estimated
fromXRD) and the cluster size fromhigh resolution TEM images
indicates that the MMNs consisted of an assembly of individual
Fig. 1 SEM images of PEGylated MMNs synthesized (a) without and (b) with
NaBH4 (0.05 g). The inset shows the TEM image of a single MMN.
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particles with sizes of less than 12 nm. EDXanalysis conrms the
composition of the MMNs (Fig. S2b†). The formation mecha-
nism of the MMNs can be described as a two stage reaction. The
nucleation of nanocrystals occurs in the primary stage of the
reaction in a supersaturated solution followed by aggregation
into larger aggregates or secondary particles.12,21 The number
density of the particles as well as the relative strength of the
anisotropic dipole–dipole and isotropic van der Waals coupling
also inuence the above mechanism.22 The nitrogen (N2)
adsorption–desorption isotherm shows a pore size distribution
having intrapores (3 nm) and interpores (30 nm) and a
specic surface area of 92 cm2 g1 (Fig. 2a). The mesoporous
nature, size of below 100 nmand large specic surface areamake
MMNs ideal nanocarriers for drug delivery applications. The
Fourier-transform infrared (FTIR) spectrum (Fig. 2b) of PEGy-
lated MMNs shows the presence of bands at 1107 and 1402 cm-1
which are due to the C–O–C ether stretching vibration of HOOC–
PEG–COOH with bands shied compared to those of the free
PEG molecule indicating its attachment on the MMNs.23
The bands at 1608 and 3400 cm1 are due to the O–H
bending and stretching frequencies of the carboxylate group
which are different and at a lower wavenumber than the free
O–H group indicating the presence of a hydrogen bond in the
EG molecule and its attachment on the surface of the MMNs.23
The thermogravimetry (TG) analysis (Fig. S3a†) shows the
sequential weight loss in different temperature ranges due to
the loss of physically adsorbed and chemically bonded water
molecules and the decomposition of organic carbonaceous
materials to form CO2 gas. The TG analysis along with the FTIR
data conrms the attachment of PEG-diacid on the MMNs.
Furthermore, the zeta potential of the MMNs was determined
and found to be 23.6 mV. The coating of PEG-diacid
enables a good colloidal stability of the MMNs in PBS, which is
necessary for their use in drug delivery applications (Fig. S3b†).
The M–H curve (Fig. S4†) shows a typical superparamagnetic
nature of the MMNs with magnetization of 57 emu g1
measured in a eld of 2 Tesla. The blocking temperature (Tb)
was found to be 100 K from the zero eld cool and eld cool
(ZFC–FC) curve. The higher magnetic moment and super-
paramagnetic nature of the MMNs are the required attributes
for magnetic hyperthermia (MHT).
3.2 In vitro and intracellular DOX release
We have further demonstrated the interaction and cellular
uptake of rhodamine-6G (lex ¼ 530 nm, lem ¼ 555 nm) labelled
MMNs by cancer cells. Fig. 3i–iii shows the appearance of
granulated red uorescence aer incubation for 4 h, which
indicates the uptake of MMNs by the HeLa cells. The higher
uptake of MMNs may be attributed due to the PEG coating,
which retards the adsorption of unwanted biomolecules on the
surface.16
The biocompatibility of MMNs was studied on mouse
broblast cells (L929) by MTS assay. We observed no signicant
cytotoxicity effect of the MMNs on the cells at concentrations of
up to 0.4 mg of MMNs per mL (in terms of the metal ion
concentration) aer 24 and 48 h of incubation (Fig. S5a and b†).
Microscopic images show that up to 0.2 mg of MMNs per mL,
the growth and morphology of the L929 cells are similar to cells
incubated in media without MMNs (control) at the corre-
sponding time intervals. However, at a concentration of 0.6 mg
of MMNs per mL, a slight shrinkage of the cells was observed
without affecting the viability of the cells. The cationic DOX was
used as a model anticancer drug for loading and release studies
of the MMNs. The DOX was loaded through electrostatic
interaction with the negatively charged carboxyl enriched
MMNs in PBS medium (pH ¼ 7.4) by mixing for 24 h. The
uorescence intensity of supernatant liquid was recorded aer
magnetic separation of DOX-bound MMNs. The uorescence
intensity of the free DOX (16 mg in 600 mL of PBS) quantied by
UV-vis absorbance with a prominent DOX peak at 490 nm,
decreased upon the addition of different amounts of MMNs
(Fig. 4a). This is obvious due to the quenching of the DOX
uorescence upon interaction with the MMNs. 80% (w/w) drug
loading was achieved under physiological conditions (pH 7.4) in
which the daunosamine group of DOX was deprotonated and its
solubility in water decreased.24 The large amount of DOX
loading could possibly be due to the high specic surface area,
negative charge and mesoporous nature of the MMNs.
Next, we investigated the release prole of DOX at different
physiological pH values. A higher release (75–80%) was
observed at a lower pH (5.2) as compared to 20–25% at a higher
pH (7.4) within 24 h (Fig. 4b). The high release of DOX in a mild
acidic environment might be due to the dissolution of PEG and
weakening of electrostatic bonding by excessive deprotonation
of the daunosamine group of the DOX.6,23 This is favourable for
Fig. 2 (a) N2 adsorption–desorption isotherms and pore size distribution (inset)
of as-synthesized MMNs. (b) FT-IR spectra of the (i) PEG-diacid coated MMNs and
(ii) bare PEG-diacid.
Fig. 3 Cellular uptake behaviour of rhodamine-6G labelled MMNs by HeLa cells
after incubation for 4 h: confocal image of (i) rhodamine-6G labeled MMNs, (ii)
differential interference contrast (DIC) image, (iii) overlay image of (i) and (ii)
showing red granulated fluorescence which confirms the presence of MMNs
inside the cancer cells.
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the effective treatment of cancer because the majority of
tumours have mildly acidic cellular environments.24,25 Addi-
tionally, the mesoporous nature of the MMNs protects the drug
payload from unwanted enzymatic degradation and protein bio-
fouling which usually happens with free DOX in blood.24
Next,we tested the antitumour ability ofDOX–MMNsonHeLa
cells. The temporal concentration response of the DOX–MMN
conjugates was monitored by the MTS assay (Fig. S6a and b†).
The IC50 values for the conjugate were found to be 3.5 and 1 mg of
DOX per mL at 24 and 48 h, respectively. Having established an
antitumour activity of the DOX–MMN conjugates, we studied in
vitro DOX release by the conjugates in HeLa cancer cells,
observed through confocal uorescence imaging (Fig. 5a and b).
The morphology of the HeLa cells was observed by incubating
them with the conjugates (0.1 mg of MMNs per mL, 20 mg
equivalent DOX per mL) for 4, 24 and 48 h (Fig. 5b-v–vii) and the
results were compared with the free DOX (20 mg mL1) treated
cells (Fig. 5b-ii–iv). Cells cultured under the same conditions
without DOX–MMNs incubation were used as a control (Fig. 5b-
i). Aer entering into the cells, the DOX was released from the
conjugates in a mildly acidic environment of late endosomes/
lysosomes (pH 4.7) due to deprotonation of the daunosamine
group of DOX (Fig. 5a). Lysotracker red was used to stain the
DOX–MMNs encapsulated lysosomes, which ismore evident due
to the appearance of an orange colour due to the overlay of green
(DOX) and red (lysotracker)orescence as shown in (Fig. 5a-i–iv).
Aer uptake for 4 h, DOX started to diffuse from the cellular
compartment to the nuclear compartment. Several reports show
that DOXdirectly intercalates withDNAor DNA topoisomerase II
and inhibits RNA synthesis to elicit its cytotoxic effect.25,26
Interestingly, we observed a good relationship between the
antitumour activity of the DOX–MMNs and the stimulation of
apoptosis. The apoptotic nuclei were observed by staining them
with a nuclear dye ethidium bromide that gave red uorescence
when excited at 518 nm. The DOX–MMNs gave green uores-
cence due to the presence of DOX. Fig. 5b-i shows that cells from
the control group exhibited evenly stained nuclei and intact
nuclear membranes showing 99% cell viability. In contrast to
this, Fig. 5b-ii–iv (DOX alone) and Fig. 5b-v–vii (DOX–MMN
conjugates) show loss of cell membrane integrity, complete DNA
fragmentation and a reduction in the size of the nucleus. These
are the most prominent morphological markers used for the
identication of apoptosis in cancer cells and represent impor-
tant events in successful chemotherapeutic treatment from
which a cancer cell cannot return to a live condition. Gao et al.
Fig. 4 (a) Fluorescence spectra of DOX solution (16 mg in 600 mL of PBS, pH 7.4)
with different concentrations of MMNs (in terms of the metal concentration) for
the preparation of DOX–MMNs and (b) release profile of DOX fromMMN solution
at pH 5.2 and pH 7.4. The measurements were made at 37 C.
Fig. 5 (a) Subcellular localization of DOX–MMNs in HeLa cells after incubation for
4 h: (a-i) DOX–MMNs (fluorescence of DOX, green color), (a-ii) lysosomal compart-
ment of cells (lysotracker dye, red), (a-iii) nucleus stained with DAPI (4,6-diamidino-
2-phenylindole, blue color), (a-iv) merged image of DOX–MMNs and lysotracker
signals (orange colour) suggest localization of DOX–MMNs in the lysosomal
compartment (pH5) of the cell. (b) In vitro efficacy of DOX–MMNs for the delivery of
DOX in cancer cells. Confocal laser scanning microscopy (CLSM) images show the
apoptosis (DNA fragmentation) in HeLa cells. (i) Control (without DOX) showing
rounded, intact nucleus; (ii–iv) with DOX (20 mg mL1) alone and (v–vii) with DOX–
MMNconjugates (0.5mgofMMNspermL in terms of themetal ion concentration
with20 mg equivalent DOXpermL) at indicated time intervals of 4, 24, and 48 h at
37 C, without any heat treatment. The green fluorescence shows DOX–MMNs, red
fluorescence shows ethidium bromide (EtBr) stained nuclei. The scale bar is 50 mm.
Enlarged images show typical apoptotic nuclei with fragmented morphology.
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have demonstrated the same approach of apoptosis induction in
MCF-7 and drug-resistant MCF-7/ADR breast cancer cells using
DOX released frommesoporous silica nanoparticles.25 Likewise,
Li and co-workers reported DNA fragmentation as a major event
in the apoptosis of HeLa cells using DOX loaded dextran nano-
particles.26 Our results show that DOX–MMN conjugates have
toxic effects comparable to those of the free DOX, although free
DOX induces more cell death. The free DOX enters into the
cytoplasm of the cancer cells through passive diffusion but is
easily effluxed by the P-glycoprotein efflux pump, active in all
types of tumour,25,27 whereas DOX–MMN conjugates are inter-
nalized via endocytosis.24,25 Drug efflux by the cancer cell is a
major hurdle for effective chemotherapeutic treatment. These
conjugates not only have the capability to reduce the toxicity of
free DOX but also help in enhancing the therapeutic efficacy of
DOX by reducing the drug efflux problem and increasing the
DOX retention time inside cancer cells.
3.3 In vitro chemo-thermal evaluation of DOX–MMNs
Previous studies have reported the extensive use of MgFe2O4
nanoparticles for magnetic hyperthermia.28,29 In order to use
DOX–MMNs for chemo-thermal therapy, the heating efficiency
of MMNs was evaluated under an AMF with a frequency of
425 kHz and strengths of 7 and 10 kA m1 s1 (Fig. 6a). The
temperature of the solution containing 0.5 mg of MMNs per mL
of PBS increased to 42–43 Cwithin 5minutes. This temperature
is recommended as the therapeutic threshold temperature
required for hyperthermia.We found a variation of the SAR value
at the two differenteld strengths, 7 kAm1 s1 (95.38Wper g of
Fe) and 10 kAm1 s1 (153.4Wper g of Fe) at axed frequency of
425 kHz. This is obvious because the SAR value increased pro-
portionally to the eld strength and frequency.9,30
Next, we investigated the rationale behind the hyperthermia
induced enhancement of the DOX toxicity. The bare MMNs and
DOX–MMN conjugates (20 mg equivalent DOX per mL) at
concentrationsof 0.5mgofMMNspermLwere incubated for24h
with cancer cells. The cells without MMNs and DOX treatment
were used as a control. Aer incubation for 24 h, the cells (2 106
cells per pellet) were subjected to an AMF of 7 kA m1 s1 at a
frequency of 425 kHz for 5minutes to evaluate the individual and
combined effect of bareMMNsandDOX–MMNconjugates on the
proliferation of cancer cells. Following magnetic hyperthermia
treatment, the cellswerewashedwithPBSandallowed togrow for
24 h. The morphology of the control and MHT treated cells were
observed by DIC and confocal imaging (Fig. 6bi–iv). The actin
laments were stainedwith phalloidin-tetramethylrhodamine-B-
isothiocyanate and the nucleus with 4,6-diamidino-2-phenyl-
indole dye (DAPI). The confocal images show plasmamembrane
distortion, blebbing, disorganization of the cytoskeleton protein
(F-actin) and shrinkage of the nucleus upon treatment, a prom-
inent marker of hyperthermia induced late apoptosis in cancer
cells (Fig. 6ii and iv). Thomas et al. also found a similar apoptosis
phenomenon when breast cancer cells (MDA-MB-231) were sub-
jected to MHT withmagnetic core silica nanoparticles (MCSNs).4
A similar approach was attempted by Prasad et al. using g-
MnxFe2xO3 for the hyperthermia treatment of cancer cells.31
The live/dead assay was performed for a qualitative assess-
ment of the dual therapy effect on the viability of cancer cells
(Fig. 7a). A quantitative estimation of cell viability was achieved
using the MTT assay (Fig. 7b). Both the live/dead and MTT assay
demonstrated a signicant increase in toxicity of the DOX–
MMNs, when combined with MHT (Fig. 7a and b). It was
observed that cells treated with MMNs and exposed to MHT
showed 45% cell death while cells treated with DOX–MMN
conjugates (20 mg equivalent DOX per mL) without MHT
exhibited 65% cell death. However, cells simultaneously treated
with DOX–MMN conjugates (20 mg equivalent DOX per mL)
and MHT resulted in cell death of up to 90%. Our results are
consistent with the ndings of Brule et al., which demonstrated
the combined effect of chemo-thermal therapy on cancer cells
using magnetic alginate microspheres. Their study showed that
the combination of a drug and magnetic hyperthermia induces
more cell death as compared to the effects of individual
Fig. 6 (a) Temperature vs. time plots of PEGylatedMMNs (5mL, 0.5 mg of MMNs
per mL in PBS in terms of the metal concentration) under AC magnetic fields of
different strengths. (b) In vitro hyperthermia (MHT) study of MMNs alone with
HeLa cells under an AC magnetic field (AMF) of 425 kHz, 7 kA m1 for 5 minutes
at 43–45 C: (b-i) differential interference contrast (DIC) image, (b-ii) confocal
image of control HeLa cells stained with phalloidin-tetramethylrhodamine-B-
isothiocyanate (red) for actin filaments and 4,6-diamidino-2-phenylindole dye
(DAPI, blue color) for the nucleus, (b-iii and iv) DIC and confocal images of MHT
treated HeLa cells showing the blebbing formation and distortion of the cell
membrane, a morphological indication of cell late apoptosis/necrosis.
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therapy.3 A similar result was reported by Lee et al. in their study
with lung cancer cells in which they showed that hyperthermia
improves the efficacy of chemotherapy using mesoporous silica
nanoparticles.32 On similar lines, the present study also
suggests that the combination of chemo-thermal therapy
induces the destruction of HeLa cancer cells more efficiently
than the individual effect of DOX or MHT treatment alone. Noh
et al. even reported the signicance of the dual therapy by
inducing more cell death in the drug resistant cancer cell line
DLD-1-ADR vs. normal cancer cells.33 With the same views as in
the studies by Noh et al., it is predicted that the problem of drug
resistant cancer cells and drug efflux, a major hurdle in the
treatment of cancer, can be solved by the application of chemo-
thermal therapy. With these features, MMNs appear to be a
potential integrated nanoparticles system combining magnetic
hyperthermia with drug delivery for effective cancer therapy.
4 Conclusions
In summary, biocompatible and biodegradable PEG coated
carboxyl-enriched MgFe2O4 MMNs with sizes less than 100 nm
have been developed to evaluate the synergistic effect of chemo-
thermal therapy in vitro. The negatively charged, mesoporous
MMNs help in terms of a high loading efficiency and pH
induced DOX release for cancer cell death. Hyperthermia
signicantly enhances the therapeutic efficacy of DOX, leading
to more cell death in comparison to the individual treatments of
hyperthermia or DOX. This study suggests that MMNs act as a
novel therapeutic mediator, having the potential to reduce the
toxicity of DOX and increase its aqueous solubility with two
therapeutic modalities, chemo- and thermal therapy in a single
system, for the effective treatment of cancer. Further studies are
ongoing for the development of DOX–MMN conjugation
through acid labile hydrazone bonds and their implication in
bimodal drug delivery andMR imaging. Additionally, the role of
Mg2+ ions in the apoptosis of cancer cells is under examination.
Acknowledgements
The study is supported by Nanomission, Department of Science
and Technology (DST) and Nanotechnology Section, Depart-
ment of Information Technology (DIT), Govt of India. We thank
Asif S. Khan for his assistance with the hyperthermia experi-
ment. The authors are also thankful to the Centre for Research
in Nanotechnology and Science (CRNTS), I. I. T. Bombay.
Notes and references
1 R. A. Petros and J. M. Desimone, Nat. Rev. Drug Discovery,
2010, 9, 615–627.
2 S. Chandra, K. C. Barick and D. Bahadur, Adv. Drug Delivery
Rev., 2011, 63, 1267–1281.
3 S. Brule, M. Levy, C. Wilhelm, D. Letourneur, F. Gazeau,
C. Menager and C. L. Visage, Adv. Mater., 2011, 23, 787–790.
4 C. R. Thomas, D. P. Ferris, J. H. Lee, E. Choi, M. H. Cho,
E. S. Kim, J. F. Stoddart, J. S. Shin, J. Cheon and J. I. Zink,
J. Am. Chem. Soc., 2010, 132, 10623–10625.
5 J. You, R. Zhang, G. Zhang, M. Zhong, Y. Liu, C. S. V. Pelt,
D. Liang, W. Wei, A. K. Sood and C. Li, ACS Nano, 2012,
158, 319–328.
6 S. P. Sherlock, S. M. Tabakman, L. Xie and H. Die, ACS Nano,
2011, 5, 1505–1512.
7 K. Yang, S. Zhang, G. Zhang, X. Sun, S. T. Lee and Z. Liu,
Nano Lett., 2010, 10, 3318–3323.
8 P. Pradhan, J. Giri, F. Rieken, C. Koch, O. Mykhaylyk,
M. Doblinger, D. Bahadur and C. Plank, J. Controlled
Release, 2010, 142, 108–121.
9 K. C. Barick, M. Aslam, Y. P. Lin, D. Bahadur, P. V. Prasad
and V. P. Dravid, J. Mater. Chem., 2009, 19, 7023–7029.
10 J. T. Jang, H. Nah, J. H. Lee, S. H. Lee, S. H. Moon, M. G. Kim
and J. Cheon, Angew. Chem., Int. Ed., 2009, 48, 1234–
1238.
11 K. C. Barick, S. Singh, N. V. Jadhav, D. Bahadur, B. N. Pandey
and P. A. Hassan, Adv. Funct. Mater., 2012, 22, 4975–4984.
Fig. 7 (a) Live/dead assay for the synergistic effect of chemo-thermal therapy in
vitro: cells were stained with calcein (green) and ethidium homodimer-1 (red) for
the visualization of live and dead cells, respectively. (b) Cells were treated with
free DOX (20 mg mL1), MMNs, and DOX–MMN conjugates (20 mg equivalent
DOX per mL). The cells without DOX and MMN incubation were used as a control.
Quantitative evaluation of cell viability was determined using the MTT assay. The
DOX–MMN efficacy was significantly enhanced when combined with hyper-
thermia (MHT), almost 90% of cancer cells died. The viability of the control cells or
DOX incubated cells was not effected by hyperthermia. Data shown are means 
SD from n ¼ 3. **P < 0.01.
This journal is ª The Royal Society of Chemistry 2013 J. Mater. Chem. B, 2013, 1, 3652–3660 | 3659
Paper Journal of Materials Chemistry B
View Article Online
12 B. Luo, S. Xu, A. Luo, W. R. Wang, S. L. Wang, J. Guo, Y. Lin,
D. Zhao and C. C. Wang, ACS Nano, 2011, 5, 1428–
1435.
13 B. Luo, S. Xu, W. F. Ma, W. R. Wang, S. L. Wang, J. Guo,
W. L. Yang, J. H. Hu and C. C. Wang, J. Mater. Chem.,
2010, 20, 7107–7113.
14 J. Ge, Y. Hu, M. Biasini, W. P. Beyermann and Y. Yin, Angew.
Chem., Int. Ed., 2007, 46, 4342–4345.
15 J. Liu, Z. Sun, Y. Deng, Y. Zou, C. Li, X. Guo, L. Xiong, Y. Gao,
F. Li and D. Zhao, Angew. Chem., Int. Ed., 2009, 48, 5875–
5879.
16 Y. Zhang, N. Kohler and M. Zhang, Biomaterials, 2002, 23,
1553–1561.
17 J. Xie, C. Xu, N. Kohler, Y. Hou and S. Sun, Adv. Mater., 2007,
19, 3163–3166.
18 C. Martinez-Boubeta, L. Balcells, R. Cristo`fol, C. Sanfeliu,
E. Rodr´ıguez and R. Weissleder, Nanomedicine:
Nanotechnology, Biology, and Medicine, 2010, 6, 362–
370.
19 K. Krishnamoorthy, J. Y. Moon, H. B. Hyun, S. K. Cho and
S. J. Kim, J. Mater. Chem., 2012, 22, 24610–24617.
20 G. Cao, Nanostructures and Nanomaterial's: Synthesis,
Properties and Applications, Imperial College Press, 2nd
edn, 2004.
21 L. T. Su, A. I. Y. Tok and F. Y. C. Boey, CrystEngComm, 2009,
11, 1880–1885.
22 A. Baskin, W. Y. Lo and P. Kral, ACS Nano, 2012, 6, 6083–
6090.
23 F. Hu, K. W. Macrenaris, E. A. Waters, E. A. S. Sikma,
A. L. Eckermann and T. J. Meade, Chem. Commun., 2010,
46, 73–75.
24 Y. Tian, L. Bromberg, S. N. Lin, T. A. Hatton and K. C. Tam,
J. Controlled Release, 2007, 121, 137–145.
25 Y. Gao, Y. Chen, X. Ji, X. He, Q. Yin, Z. Zhang, J. Shi and Y. Li,
ACS Nano, 2011, 5, 9788–9798.
26 Y. L. Li, L. Zhu, Z. Liu, R. Cheng, F. Meng, J. H. Cui, S. J. Ji
and Z. Zhong, Angew. Chem., Int. Ed., 2009, 48, 9914–9918.
27 F. M. Kievita, F. Y. Wang, C. Fang, H. Mok, K. Wang,
J. R. Silberb, R. G. Ellenbogen and M. Zhang, J. Controlled
Release, 2011, 152, 76–83.
28 S. Yukumi and Y. Watanabe, Int. J. Hyperthermia, 2009, 25,
416–421.
29 A. Chalkidou, K. Simeonidis, M. Angelakeris, T. Samaras,
C. Martinez-Boubeta, L. Balcells, K. Papazisis,
C. Dendrinou-Samara and O. Kalogirou, J. Magn. Magn.
Mater., 2011, 323, 775–780.
30 L. Lartigue, P. Hugouneng, D. Alloyeau, S. P. Clarke, M. Levy,
J. C. Bacri, R. Bazzi, D. F. Brougham, C. Wilhelm and
F. Gazeau, ACS Nano, 2012, 6, 10935–10949.
31 N. K. Prasad, K. Rathinamy, D. Panda and D. Bahadur,
J. Mater. Chem., 2007, 17, 5042–5051.
32 H. Lee, S. Kim, B. Choi, M. Park, J. lee, S. Jeong, E. K. Choi,
B. Lim, C. Kim and H. Park, Int. J. Hyperthermia, 2011, 27,
698–707.
33 S. Noh, W. Na, J. Jang, J. Lee, E. J. Lee, S. H. Moon, Y. Lim,
J. S. Shin and J. Cheon, Nano Lett., 2012, 6, 5266–5273.
3660 | J. Mater. Chem. B, 2013, 1, 3652–3660 This journal is ª The Royal Society of Chemistry 2013
Journal of Materials Chemistry B Paper
View Article Online
